TNF and inflammatory bowel disease: TNFα inhibitor dose escalation and initiation of high‐dose corticosteroid were associated with switching in RD patients while dose escalation of the TNFα inhibitor or immunomodulator, initiation of high‐dose corticosteroid treatment, and TNFα inhibitor serum concentration measurement were associated with switching in IBD patients.